Precision Therapeutics
for Brain Diseases

Kynexis is advancing the first potential precision medicine for the treatment of cognitive impairment associated with schizophrenia (CIAS).

Our Purpose

Restore brain function to enable a better life for people suffering with schizophrenia

A significant challenge in improving the lives of people who have schizophrenia has been developing a treatment for CIAS, which is a major cause of disability for over 24 million affected people worldwide. The dysregulation of kynurenic acid is hypothesized to cause cognitive impairment in people with schizophrenia, and we are taking a biomarker-based approach to identify patients most likely to benefit from our potential new therapy.

Understand the causal human biology in cognitive impairment associated with schizophrenia (CIAS)

For decades, research on novel potential therapies for neuropsychiatric disorders relied primarily on animal models. At Kynexis, we use a human biology-based approach for our target rationale, a causal biomarker approach to assert our mechanism of action in clinical development, and a human genetics approach to identify responder sub-populations. We believe that this convergence of human data for rationale, biomarkers, and genetics uniquely positions this program for success in CIAS and possibly additional indications as well.

Targeting a key mechanism in the kynurenine pathway.

Based on the pioneering work of two Kynexis founders – Dr. Carol Tamminga, University of Texas Southwestern, Dallas, and Dr. Robert Schwarcz, University of Maryland, Baltimore – we are taking a precision approach to target KAT-II, a key enzyme in the kynurenine pathway. KYN-5356 is a potential first-in-class small molecule that is a potent and highly selective KAT-II inhibitor, solving the challenges of previous attempts at KAT-II inhibition.

APPROACH

Management Team

Kees Been

Chief Executive Officer

View Bio

Jens Wendland, M.D.

Chief Medical Officer

View Bio

Thomas Rasmussen

Chief Operating Officer

View Bio

Nancy Van Osselaer

Chief Development Officer

View Bio

Board of Directors

Peter Høngaard

Executive Chairman

View Bio

Christer Köhler

Founding Director

View Bio

Dmitrij Hristodorov

Investor Director

View Bio

Raúl Martín-Ruiz

Investor Director

View Bio

Jacob Lange Moresco

Investor Director

View Bio

Tim Lohoff

Board Observer

View Bio

SCIENTIFIC FOUNDERS

Robert Schwarcz

Professor at the University of Maryland School of Medicine

Carol Tamminga

Professor at the University of Texas UT Southwestern Medical Center

SCIENTIFIC ADVISORY BOARD

Robert Schwarcz

Professor at the University of Maryland School of Medicine

Robert Schwarcz

Executive Chairman

Carol Tamminga

Professor at the University of Texas UT Southwestern Medical Center

Carol Tamminga

Executive Chairman

Leadership

Tackling brain diseases with an accomplished team of industry experts.

At Kynexis, we are pioneering the next era of treatments for brain diseases by advancing the first precision medicine for CIAS. Harnessing the power of human genetics, biomarkers, and large-scale data, our foundational science is the driving force behind our mission to transform the treatment paradigm of schizophrenia. 

If you want to learn more about the work at Kynexis or are interested in joining our team of trailblazers, contact us. 

Contact

By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.